a, Intraperitoneal mesothelioma model. Luciferase-expressing H2373 cells introduced to the peritoneal cavity of NSG mice (n = 10 animals for miRNA-206 group; n = 9 for rest) established tumor after 1 week. Tumor progression was monitored for 3 weeks after a single injection of SFH. b, Tumor progression as a function of SFH composition. ROI radiant flux at each time was normalized to day 0 for each treatment group. Statistics at day 21 derived from surviving mice; n = 7 for empty SFH and scrambled miRNA-treated group, n = 8 for miRNA-215-treated group and n = 9 for rest; One-way ANOVA with Tukey’s multiple-comparisons test. c,d, Tumor luminescence and survival curves of mice treated with SFHs, Log-rank (Mantel-Cox) test. e, Intrapleural mesothelioma model. Luciferase-expressing MB52 cells introduced in the pleural cavity of NSG mice (n = 10 animals for empty SFH & miRNA-215 group and n = 9 for rest) established tumor after 1 week. Tumor progression was monitored for 2 weeks after a single injection of SFH. f, Tumor progression as a function of SFH composition. ROI radiant flux at each time point was normalized to day 0 for each treatment group. Statistics at day 14 derived from surviving mice, n = 9 for empty SFH & miRNA-206 groups, n = 10 for miRNA-215 group and n = 8 for rest; * p = 0.035, One-way ANOVA, # p = 0.045, Tukey’s multiple-comparisons test between scrambled miRNA and miRNA-206 groups. g,h Tumor luminescence and survival curves of mice treated with SFHs, Log-rank (Mantel-Cox) test. i, Mesothelioma xenograft resection model. Luciferase-expressing MB52 cells were subcutaneously injected into the left and right flanks of NSG mice. After 5 weeks (tumor volume ~200 mm3), tumors were resected and SFH of indicated compositions were syringe-administered to the resection sites. j, Tumor luminescence of mice treated with SFHs. k & l, Total radiant flux at tumor ROI for different treatment groups at day 28 post-administration of SFH, n = 4 animals, two-tailed Mann Whitney test. Data = mean ± SEM for b,f,k,l.